De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacogenomics (London)

• Publication date

  2015-08-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pgs.15.88PMID 26257318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

  2015cited by this paper
• Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast

  2015cited by this paper
• ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

  2014cited by this paper
• Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer

  2014cited by this paper
• Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

  2014cited by this paper
• PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

  2014cited by this paper
• Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

  2014cited by this paper
• Expression and significance of Wnt signaling components and their target genes in breast carcinoma.

  2014cited by this paper
• Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.

  2014cited by this paper
• Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

  2014cited by this paper
• Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer

  2014cited by this paper
• IGKC and FcγR genotypes and humoral immunity to HER2 in breast cancer.

  2014cited by this paper
• Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

  2014cited by this paper
• A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer

  2014cited by this paper
• PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.

  2013cited by this paper
• Activating HER2 mutations in HER2 gene amplification negative breast cancer.

  2013cited by this paper
• Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

  2013cited by this paper
• Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.

  2013cited by this paper
• Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013cited by this paper
• The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis

  2013cited by this paper
• Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

  2013cited by this paper
• Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer

  2013cited by this paper
• CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.

  2013cited by this paper
• HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

  2013cited by this paper
• Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

  2013cited by this paper
• HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients

  2013cited by this paper
• Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001).

  2013cited by this paper
• Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

  2013cited by this paper
• Calpain 2 Regulates Akt-FoxO-p27Kip1 Protein Signaling Pathway in Mammary Carcinoma*

  2012cited by this paper
• Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

  2012cited by this paper
• Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response

  2012cited by this paper
• Sequence analysis of mutations and translocations across breast cancer subtypes

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

  2012cited by this paper
• Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

  2011cited by this paper
• FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.

  2011cited by this paper
• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

  2011cited by this paper
• Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials

  2011cited by this paper
• Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Calpain‐1 expression is associated with relapse‐free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy

  2011cited by this paper
• Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer

  2010cited by this paper
• PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

  2010cited by this paper
• Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.

  2010cited by this paper
• Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

  2010cited by this paper
• Diverse somatic mutation patterns and pathway alterations in human cancers.

  2010cited by this paper
• The PI3K pathway as drug target in human cancer.

  2010cited by this paper
• Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

  2009cited by this paper
• Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

  2009cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

  2008cited by this paper
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

  2008cited by this paper
• NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

  2008cited by this paper
• Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.

  2007cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• CDC25 phosphatases in cancer cells: key players? Good targets?

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Non-transcriptional control of DNA replication by c-Myc

  2007cited by this paper
• Monoclonal antibody mechanisms of action in cancer

  2007cited by this paper
• Mutations of HER2 gene in HER2-positive metastatic breast cancer.

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation

  2006cited by this paper
• Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells

  2005cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

  2004cited by this paper
• P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

  2004cited by this paper
• Minireview: Cyclin D1: normal and abnormal functions.

  2004cited by this paper
• FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

  2003cited by this paper
• PTEN and cancer.

  2003cited by this paper
• FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

  2003cited by this paper
• FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal

  2002cited by this paper
• Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

  2002cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The PI3K-PDK1 connection: more than just a road to PKB.

  2000cited by this paper
• Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

  2000cited by this paper
• ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

  2000cited by this paper
• Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

  1999cited by this paper
• Mechanisms of apoptosis by c-Myc

  1999cited by this paper
• Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.

  1998cited by this paper
• The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.

  1998cited by this paper
• Control of apoptosis and mitotic spindle checkpoint by survivin

  1998cited by this paper
• A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

  1997cited by this paper
• Cyclin E-CDK2 is a regulator of p27Kip1.

  1997cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit.

  1992cited by this paper
• Four genes for the calpain family locate on four distinct human chromosomes.

  1990cited by this paper
• Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• The role of genetics and epigenetics in breast cancer: A comprehensive review of metastasis, risk factors, and future perspectives

  2025cites this paper
• Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.

  2024cites this paper
• Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China

  2024influential citation
• Screening of GPCR drugs for repurposing in breast cancer

  2022cites this paper
• Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice.

  2020cites this paper
• Cullin7 Enhances Resistance to Trastuzumab Therapy in Her2 Positive Breast Cancer via Degrading IRS-1 and Downregulating IGFBP-3 to Activate the PI3K/AKT Pathway.

  2019cites this paper
• NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.

  2019cites this paper
• SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab-resistant ovarian cancer model

  2017cites this paper
• ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.

  2016cites this paper
• Engineering strategies for ABD-derived affinity proteins for therapeutic and diagnostic applications

  2016cites this paper
• Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

  2015cites this paper